(NASDAQ: AXSM) Axsome Therapeutics's forecast annual revenue growth rate of 49.59% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Axsome Therapeutics's revenue in 2024 is $270,600,000.On average, 7 Wall Street analysts forecast AXSM's revenue for 2024 to be $16,600,312,621, with the lowest AXSM revenue forecast at $15,445,467,481, and the highest AXSM revenue forecast at $17,746,440,875. On average, 7 Wall Street analysts forecast AXSM's revenue for 2025 to be $29,234,063,571, with the lowest AXSM revenue forecast at $25,532,419,406, and the highest AXSM revenue forecast at $35,321,386,513.
In 2026, AXSM is forecast to generate $43,404,544,498 in revenue, with the lowest revenue forecast at $40,661,426,063 and the highest revenue forecast at $47,819,694,125.